<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02905942</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-JYL-20150830</org_study_id>
    <nct_id>NCT02905942</nct_id>
  </id_info>
  <brief_title>PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>A Single Center Randomized Controlled Trial of the Efficacy and Safety of PEG-rhG-CSF After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF on the&#xD;
      recovery of hematopoietic function after autologous stem cell transplantation in patients&#xD;
      with lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At present, there is few related research of Recombinant Human Granulocyte Colony-stimulating&#xD;
      Factor applying to AHSCT in China. The purpose of the study is to evaluate the efficacy and&#xD;
      safety of PEG-rhG-CSF in lymphoma patients after autologous hematopoietic stem cell&#xD;
      transplantation. Eligible patients were randomly assigned to PEG-rhG-CSF group or rhG-CSF&#xD;
      group. Patients in PEG-rhG-CSF group received PEG-rhG-CSF day +1 after transplantation with a&#xD;
      dose of 100μg/kg. Patients with the weight more than 45kg were suggested a dose of 6 mg.&#xD;
      Patients in control group received rhG-CSF day +1 after transplantation with a dose of 5μg/kg&#xD;
      once per day until the recovery of neutrophil.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to neutrophil engraftment</measure>
    <time_frame>30days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in PEG-rhG-CSF group received PEG-rhG-CSF day +1 after transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhG-CSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in control group received rhG-CSF day +1 after transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-rhG-CSF</intervention_name>
    <description>PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.</description>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhG-CSF</intervention_name>
    <description>rhG-CSF was given day +1 after transplantation with a dose of 5μg/kg once per day</description>
    <arm_group_label>rhG-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with age between 18 and 65 years.&#xD;
&#xD;
          2. Lymphoma patients with the requirement for autologous hematopoietic stem cell&#xD;
             transplantation.&#xD;
&#xD;
          3. The collected CD34+ cells≥1×10E6/kg.&#xD;
&#xD;
          4. ECOG score ≤2.&#xD;
&#xD;
          5. Heart and lung is normal.&#xD;
&#xD;
          6. Blood creatinine ≤1.5×ULN.&#xD;
&#xD;
          7. ALT, AST, TBIL ≤2 ×ULN&#xD;
&#xD;
          8. Not in pregnancy.&#xD;
&#xD;
          9. Written informed consent are acquired.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had received autologous hematopoietic stem cell transplantation or allogeneic&#xD;
             transplantation.&#xD;
&#xD;
          2. Severe or uncontrolled infectious diseases: HIV, HCV, syphilis, ALT, chronic hepatitis&#xD;
             B.&#xD;
&#xD;
          3. Serious complications, such as severe infection, heart, lung, liver and kidney&#xD;
             dysfunction.&#xD;
&#xD;
          4. LVEF &lt;55%.&#xD;
&#xD;
          5. Allergic to the product or other biological products from genetically engineered&#xD;
             Escherichia coli strains.&#xD;
&#xD;
          6. Refused to take contraceptive measures during the study period and the subsequent 1&#xD;
             years.&#xD;
&#xD;
          7. Severe mental or neurological disorders.&#xD;
&#xD;
          8. Serious heart, lung, central nervous system disorders.&#xD;
&#xD;
          9. Sickle cell anemia, hemolytic anemia and other hematologic diseases.&#xD;
&#xD;
         10. Participate in other drugs clinical trials 30 days before the screening.&#xD;
&#xD;
         11. Other situation that investigators consider as contra-indication for this study.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Zhu, MD</last_name>
    <phone>+86-10-88196596</phone>
    <email>zj@bjcancer.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Zhu, MD</last_name>
      <phone>+86-10-88196596</phone>
      <email>zj@bjcancer.org</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jun Zhu</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

